Q2 2026 saw net income surge to $826M and Adjusted EBITDA rise 16.3% to $1.304B, with both Ambulatory and Hospital segments delivering strong revenue and margin growth. FY 2026 guidance was raised for Adjusted EBITDA and free cash flow, and share repurchase authorization increased by $2B.Original d…
Q2 2026 saw net income surge to $826M and Adjusted EBITDA rise 16.3% to $1.304B, with both Ambulatory and Hospital segments delivering strong revenue and margin growth. FY 2026 guidance was raised for Adjusted EBITDA and free cash flow, and share repurchase authorization increased by $2B.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
